Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02049489 : A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma
PhasePhase 1
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

1. Any recurrence of a glioblastoma multiforme

2. ? 18 years of age

3. Human leukocyte antigen HLA A2 positive

4. Karnofsky Performance Score (KPS) of ? 70%

5. Baseline hematologic studies and chemistry profiles must meet the following criteria:

- hemoglobin (Hgb) > 9.9 g/dL

- absolute neutrophil count (ANC) > 1000/mm3

- platelet count > 100,000/mm3

- blood urea nitrogen (BUN) < 30 mg/dL

- creatinine < 2 mg/dL

- alkaline phosphatase (ALP), aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) < 4x upper limit of normal (ULN)

- prothrombin time (PT) and activated partial thromboplastin time (PTT) ? 1.6 x
control unless therapeutically warranted

6. Female patients of child bearing potential must have negative serum pregnancy test

7. If not surgically sterile, male and female patients of childbearing age must use
double barrier contraception (hormonal; intrauterine device; barrier)

8. Written informed consent, Release of Medical Records Form and HIPAA reviewed and
signed by patient or legally authorized representatives

9. Ability to understand and the willingness to sign a written informed consent

10. Any Grade 3 or 4 toxicities (according to NCI CTCAE) resolved for at least 2 weeks
prior to first treatment

Exclusion Criteria:

1. Radiosurgery including Gamma Knife, linear accelerator based radiosurgery, CyberKnife
and placement of Gliadel wafer

2. Presence of any other active malignancy or prior history of malignancy, except for:
basal cell carcinoma of the skin, cervical carcinoma in situ, early stage prostate
carcinoma not requiring active treatment

3. New York Heart Association >/= Grade 3 congestive heart failure within 6 months prior
to study entry

4. Uncontrolled or significant cardiovascular disease, including:

- Myocardial infarction and transient ischemic attack or stroke within 6 months
prior to enrollment

- Uncontrolled angina within 6 months

- Diagnosed or suspected congenital long QT syndrome

- Any history of clinically significant ventricular arrhythmias (such as
ventricular tachycardia, ventricular fibrillation, or Torsades de pointes);

- Clinically significant abnormality on electrocardiogram (ECG)

5. Pulmonary disease including or greater than grade 2 dyspnea or laryngeal edema, grade
3 pulmonary edema or pulmonary hypertension according to CTCAE 4.03

6. Severe acute or chronic medical or psychiatric condition that could increase the risk
associated with trial participation or trial drug administration or could interfere
with the interpretation of trial results and, in the judgment of the investigator,
would make the patient inappropriate for entry into the trial. This includes but is
not limited to the following:

1. Immunosuppressive disease

2. Chronic renal disease / failure

3. Concurrent neurodegenerative disease,

4. Dementia or significantly altered mental status that would prohibit the
understanding or rendering of informed consent and compliance with the
requirements of the protocol.

7. Presence of an acute infection requiring active treatment with
antibiotics/antivirals; prophylactic administration is allowed

8. Known history of an autoimmune disorder

9. Known human immunodeficiency virus positivity or acquired immunodeficiency syndrome
related illness or other serious medical condition

10. Breastfeeding

11. Received any other therapeutic investigational agent within 30 days of screening,
except for immunotherapy. Patients with previous immunotherapy are not eligible
regardless of timing.

12. Contraindication to MRI

13. Foreseeable condition which would preclude the reduction of steroids (dexamethasone)
to a maximum of 2 mg BID within a week prior to apheresis -
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557